Citius Pharmaceuticals (CTXR) AI Stock Analysis

• Market Cap: $8.80M
• Dividend Yield: N/A
• Average Volume (3M): 462.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: N/A
• EPS Growth: 8.99%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -5.80
• Shares Outstanding: 9,360,335
• 10 Day Avg. Volume: 1,185,754
• 30 Day Avg. Volume: 462,043
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 325.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Citius Pharmaceuticals' stock score reflects the company's financial challenges, characterized by ongoing losses and reliance on external funding. Technical analysis suggests bearish trends with potential short-term rebound opportunities. Valuation remains speculative due to the negative P/E ratio and absence of dividends. The company's future hinges on achieving revenue growth and operational efficiency improvements.

Positive Factors

Clinical Trial Success

Citius announced positive top-line results from its pivotal Phase 3 clinical trial with Mino-Lok, showing potential to have two therapies in commercialization by first-half 2026.

Partnership Benefits

The combination of Lymphir and Keytruda showed clinical benefits in patients with recurrent solid tumors.

Regulatory Milestone

Citius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.

Negative Factors

Funding Risks

Risks include failure of clinical trials, regulatory requirements for additional studies, and potential need to raise additional funds under poor market conditions.

Regulatory Delays

Completing the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Revenue Risk

Timelines for the NDA submission of Mino-Lok are uncertain, leading to an increase in the revenue risk adjustment.

Citius Pharmaceuticals Business Overview & Revenue Model

Company Description

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

How the Company Makes Money

Citius Pharmaceuticals generates revenue through the development and commercialization of its pipeline of proprietary and collaborative pharmaceutical products. Key revenue streams include sales from FDA-approved products, licensing agreements, and strategic partnerships with other pharmaceutical companies. Citius focuses on advancing its clinical-stage products to commercialization, where it can earn revenues from product sales and royalties. Significant partnerships with healthcare organizations and research institutions also contribute to its earnings by facilitating product development and expanding market reach. Additionally, the company may receive milestone payments based on achieving specific regulatory or commercial objectives.

Citius Pharmaceuticals Financial Statement Overview

Summary

Citius Pharmaceuticals faces significant challenges typical of early-stage biotech firms, with ongoing losses and reliance on external financing. The company's financial health is stable in terms of assets and equity, but cash burn and lack of revenue generation remain critical concerns.

Income Statement

Citius Pharmaceuticals shows a challenging income statement with negative gross profit and net income, primarily due to high operating expenses. The company has not yet generated significant revenue, with the most recent TTM (Trailing-Twelve-Months) total revenue being minimal. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies. Revenue growth is difficult to assess due to negligible sales figures.

Balance Sheet

The balance sheet reflects a moderate financial structure with a reasonable debt-to-equity ratio and positive equity. However, the company has been relying heavily on equity financing, as evidenced by frequent capital raises, which could dilute shareholder value. The equity ratio remains strong, indicating a solid foundation of assets relative to liabilities.

Cash Flow

Citius Pharmaceuticals has a negative free cash flow and operating cash flow, highlighting cash burn issues typical for biotechnology companies in development phases. The cash flow from financing activities indicates reliance on external funding. There is no positive free cash flow growth, and the operating cash flow to net income ratio suggests inefficiencies in converting income to cash.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
155.93K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-104.92K	0.00	-194.32K	-179.68K	-164.87K	-152.36K
	EBIT
-42.69M	0.00	-36.73M	-33.32M	-23.53M	-17.71M
	EBITDA
-42.53M	0.00	-36.73M	-32.88M	-22.88M	-17.38M
	Net Income Common Stockholders
-39.68M	-39.43M	-32.54M	-33.64M	-23.13M	-17.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
216.00	3.25M	26.48M	41.71M	70.07M	13.86M
	Total Assets
216.00	116.65M	103.61M	114.00M	142.43M	43.77M
	Total Debt
20.69K	262.87K	481.25K	678.23K	855.47K	1.35M
	Net Debt
20.48K	-2.99M	-26.00M	-41.03M	-69.22M	-12.51M
	Total Liabilities
26.63K	42.55M	12.18M	10.57M	9.65M	10.10M
	Stockholders Equity
-26.41K	70.08M	90.83M	102.83M	132.18M	33.67M
Cash Flow		Free Cash Flow
-26.79M	-28.20M	-29.06M	-28.36M	-64.26M	-16.93M
	Operating Cash Flow
-26.79M	-28.20M	-29.06M	-28.36M	-24.25M	-16.93M
	Investing Cash Flow
-5.00M	-5.00M	0.00	0.00	-40.01M	-1.83K
	Financing Cash Flow
12.55M	9.97M	13.83M	0.00	120.47M	22.90M

Citius Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 1.30, below the 50-day MA of 1.76, and below the 200-day MA of 8.53, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 30.99 is Neutral, neither overbought nor oversold. The STOCH value of 31.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.

Citius Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
CTXR	42 Neutral	$8.80M	―	-52.85%	―	―	8.99%
SABS	39 Underperform	$10.96M	―	-81.92%	―	-40.94%	51.90%
SPRB	38 Underperform	$12.02M	―	-57.55%	―	-1.40%	35.83%
PSTV	37 Underperform	$12.75M	―	249.03%	―	18.54%	50.37%
MRKR	34 Underperform	$11.03M	―	-65.81%	―	-3.23%	38.05%
MTVA	23 Underperform	$12.55M	―	-224.18%	―	―	-75.88%